Repurposing existing FDA-approved inhibitors may provide new treatment approach for ovarian cancer – Tinas Wish

News

Repurposing existing FDA-approved inhibitors may provide new treatment approach for ovarian cancer

Repurposing existing FDA-approved inhibitors may provide new treatment approach for ovarian cancer

“Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.” CLICK HERE to read more about the research led by Tina’s Wish researcher Rugang Zhang, PhD.

To read more about Dr. Zhang’s work as part of our Consortium Grant, CLICK HERE.